^{Cccc stock Which C4 Therapeutics insiders have been selling company stock? The following insiders have sold CCCC shares in the last 24 months: Adam Crystal ($681,450.00), Elena Prokupets ($5,927,870.77), Jolie Siegel ($562,500.00), Malcolm Salter ($146,017.00), and Stewart Fisher ($814,680.00).Find the latest CCC Intelligent Solutions Holdings Inc. (CCCS) stock quote, history, news and other vital information to help you with your stock trading and investing.CCCC stock closed at $3.37 and is down -$0.08 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. CCCC has a roughly average overall score of 51 meaning the stock holds a better value than 51% of stocks at its current price.See CCCC Report A rating of 70 puts C4 Therapeutics Inc ( CCCC ) near the top of the Healthcare sector according to InvestorsObserver . C4 Therapeutics Inc's score of 70 means that it ranks higher than 70% of stocks in the sector.Jul 8, 2023 · The stock is rated as a Hold by 4 analyst(s), 6 recommend it as a Buy and 0 called the CCCC stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 2 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is ... During the last session, C4 Therapeutics Inc. (NASDAQ:CCCC)’s traded shares were 0.34 million, with the beta value of the company hitting 2.02. At the end of the trading day, the stock’s price was $3.23, reflecting an intraday loss of -2.42% or -$0.08. The 52-week high for the CCCC share2 days ago · The latest C4 Therapeutics stock prices, stock quotes, news, and CCCC history to help you invest and trade smarter. Menu icon A vertical stack of three evenly spaced horizontal lines. Mar 23, 2023 · Insiders who bought US$116k worth of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) stock at an average buy price of US$7.39 over the last year may be disappointed by the recent 13% decrease in the stock ... CCCC Signals & Forecast. There are few to no technical positive signals at the moment. The C4 Therapeutics Inc stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above ...Aug 22, 2023 · Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for CCCC stock stock is $8.17, which predicts an increase of 151.38%. The lowest target is $3.00 and the highest is $17. On average, analysts rate CCCC stock stock as a hold. CCCC Stock Summary Of note is the ratio of C4 THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; only 11.21% of US stocks have a lower such ratio. As for revenue growth, note that CCCC's revenue has grown -40.88% over the past 12 months; that beats the revenue growth of merely 6.11% of US companies in ... raysweather The stock's open price was 2.955. Stay informed regarding CCCC Stock and understand the value of trading C4 TherapeuticsInc now. Get the latest C4 TherapeuticsInc detailed stock quotes, stock trade data, stock price info, and performance analysis, including CCCC Stock investment advice, charts, stats and more. screenshot hp In last trading session, C4 Therapeutics Inc. (NASDAQ:CCCC) saw 0.63 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $4.38 trading at -$0.29 or -6.21% at ring of the bell on the day assigns it a market valuation of $211.25M. That closingC4 Therapeutics Inc (CCCC) stock is trading at $3.10 as of 2:06 PM on Monday, Apr 10, a decline of -$0.20, or -6.21% from the previous closing price of $3.30. The stock has traded between $3.07 and $3.51 so far today. Volume today is light. So far 229,641 shares have traded compared to average volume of 616,509 shares.Jul 7, 2023 · These Healthcare stocks are trading higher:-Castle Biosciences Inc stock is trading at $20.64, a rise of $7.36, or 54.97%, on high volume.Castle Biosciences Inc gets a Sentiment Score of Very Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $33.63. C4 Therapeutics Inc. (NASDAQ:CCCC)’s traded shares stood at 0.46 million during the last session. At the close of trading, the stock’s price was $8.54, to imply a decrease of -5.32% or -$0.48 in intraday trading. The CCCC share’s 52-week high remains $30.56, putting it -257.85% down since thatOverview Stock Screener Earnings Calendar Sectors Nasdaq | CCCC U.S.: Nasdaq C4 Therapeutics Inc. Watch list Closed Last Updated: Sep 7, 2023 4:00 p.m. EDT Delayed quote $ 2.3300 -0.0500...WATERTOWN, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science to develop a new generation of small-molecule medicines and transform how disease is treated, Read More. Jul 5, 2023.Track C4 Therapeutics Inc (CCCC) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors tower of fantasy reviewC4 Therapeutics, Inc. Common Stock (CCCC) Nasdaq Listed 0 No Notifications Add to Watchlist Add to Portfolio Quotes Mar 17, 2023 10:15 am 11:05 am 11:55 am 1:05 pm 2:00 pm 2:50 pm 3:35 pm...C4 Therapeutics Inc. advanced stock charts by MarketWatch. View CCCC historial stock data and compare to other stocks and exchanges. WATERTOWN, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science to develop a new generation of small-molecule medicines and transform how disease is treated, Read More. Jul 5, 2023.Sep 1, 2023 · According to 6 analysts, the average rating for CCCC stock is "Hold." The 12-month stock price forecast is $8.17, which is an increase of 255.22% from the latest price. C4 Therapeutics, Inc. Common Stock (CCCC) Nasdaq Listed 0 No Notifications Add to Watchlist Add to Portfolio Quotes Mar 17, 2023 10:15 am 11:05 am 11:55 am 1:05 pm 2:00 pm 2:50 pm 3:35 pm... Mar 1, 2023 · As of March 1, 2023, C4 Therapeutics Inc’s stock price is $5.05, which is down 4.27% from its previous closing price. At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics ... CCCC stock returns are also predicted based on historical data. According to our research, CCCC stock is a good long-term investment. CCCC share price has been in a bull cycle for the past year. krasnodar russia Nov 23, 2022 · -Jupiter Wellness Inc stock is trading at $1.02, a decline of $0.17, or 14.29%, on average volume. Jupiter Wellness Inc. gets a Sentiment Score of Bearish from InvestorsObserver . -C4 Therapeutics Inc ( CCCC ) stock is trading at $8.36, a drop of $1.02, or 11.94%, on low volume. CCCC Earnings Date and Information. C4 Therapeutics last posted its earnings results on August 8th, 2023. The reported ($0.73) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.01. The firm had revenue of $2.66 million for the quarter, compared to analysts' expectations of $8.65 million.CCCC 52-Week Range: $19.81 - $51.21 According to data from Benzinga Pro, the stock was down 50.8% at $11.27 at time of publication. Photo: jarmoluk from Pixabay.Jul 8, 2023 · The stock is rated as a Hold by 4 analyst(s), 6 recommend it as a Buy and 0 called the CCCC stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 2 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is ... Jul 8, 2023 · The stock is rated as a Hold by 4 analyst(s), 6 recommend it as a Buy and 0 called the CCCC stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 2 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is ... What is the target price for C4 Therapeutics (CCCC) stock? A. The latest price target for C4 Therapeutics ( NASDAQ: CCCC) was reported by HC Wainwright & Co. on Wednesday, August 9, 2023. The ...Find the latest C4 Therapeutics, Inc. (CCCC) stock quote, history, news and other vital information to help you with your stock trading and investing. vcs scheduling C4 Therapeutics Inc stock is lower by 10.19% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. C4 Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CCCC!C4 Therapeutics, Inc. Common Stock (CCCC) Nasdaq Listed 0 No Notifications Add to Watchlist Add to Portfolio Quotes Mar 17, 2023 10:15 am 11:05 am 11:55 am 1:05 pm 2:00 pm 2:50 pm 3:35 pm...C4 Therapeutics Inc. advanced stock charts by MarketWatch. View CCCC historial stock data and compare to other stocks and exchanges.These Healthcare stocks are trading higher:-Castle Biosciences Inc stock is trading at $20.64, a rise of $7.36, or 54.97%, on high volume.Castle Biosciences Inc gets a Sentiment Score of Very Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $33.63.The stock is rated as a Hold by 4 analyst(s), 6 recommend it as a Buy and 0 called the CCCC stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 2 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is ...During the last session, C4 Therapeutics Inc. (NASDAQ:CCCC)’s traded shares were 0.31 million. At the end of the trading day, the stock’s price was $8.17, reflecting an intraday gain of 7.78% or $0.59. The 52-week high for the CCCC share is $26.80, that puts it down -228.03 from that peaNov 8, 2022 · See CCCC Report A rating of 70 puts C4 Therapeutics Inc ( CCCC ) near the top of the Healthcare sector according to InvestorsObserver . C4 Therapeutics Inc's score of 70 means that it ranks higher than 70% of stocks in the sector. Find market predictions, CCCC financials and market news. View live C4 Therapeutics, Inc. chart to track its stock's price action. C4 Therapeutics Inc stock is lower by 10.19% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. C4 Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CCCC! urbabydollxo leaked Feb 24, 2023 · As of February 24, 2023, 4:00 PM CST, C4 Therapeutics Inc’s stock price was $5.33. C4 Therapeutics Inc is down 11.46% from its previous closing price of $6.02. During the last market session, C4 Therapeutics Inc’s stock traded between $5.63 and $6.17. Currently, there are 0.00 million shares of C4 Therapeutics Inc stock available for purchase. As of February 24, 2023, 4:00 PM CST, C4 Therapeutics Inc’s stock price was $5.33. C4 Therapeutics Inc is down 11.46% from its previous closing price of $6.02. During the last market session, C4 Therapeutics Inc’s stock traded between $5.63 and $6.17. Currently, there are 0.00 million shares of C4 Therapeutics Inc stock available for purchase.Find the latest C4 Therapeutics, Inc. (CCCC) stock quote, history, news and other vital information to help you with your stock trading and investing.Find market predictions, CCCC financials and market news. View live C4 Therapeutics, Inc. chart to track its stock's price action. Jul 5, 2023 · WATERTOWN, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science to develop a new generation of small-molecule medicines and transform how disease is treated, Read More. Jul 5, 2023. C4 Therapeutics Inc. (NASDAQ:CCCC)’s traded shares stood at 0.46 million during the last session. At the close of trading, the stock’s price was $8.54, to imply a decrease of -5.32% or -$0.48 in intraday trading. The CCCC share’s 52-week high remains $30.56, putting it -257.85% down since that fountain of praise Jezperklauzen/iStock via Getty Images. The shares of C4 Therapeutics ( NASDAQ: CCCC) lost more than half of their value on Friday after the clinical-stage biotech disclosed data from a group of ...Mentioned in this article. CCCC 0.00%. 52. See CCCC Report. InvestorsObserver is giving C4 Therapeutics Inc (CCCC) an Analyst Rating Rank of 24, meaning CCCC is ranked higher by analysts than 24% of stocks. The average price target for CCCC is $21 and analyst’s rate the stock as a Buy. Wall Street analysts are rating CCCC a Buy today.C4 Therapeutics Stock Earnings. The value each CCCC share was expected to gain vs. the value that each CCCC share actually gained. C4 Therapeutics ( CCCC) reported Q1 2023 earnings per share (EPS) of -$0.71, beating estimates of -$0.75 by 5.10%. In the same quarter last year, C4 Therapeutics 's earnings per share (EPS) was -$0.65.C4 Therapeutics Inc. Annual balance sheet by MarketWatch. View all CCCC assets, cash, debt, liabilities, shareholder equity and investments.-Jupiter Wellness Inc stock is trading at $1.02, a decline of $0.17, or 14.29%, on average volume. Jupiter Wellness Inc. gets a Sentiment Score of Bearish from InvestorsObserver . -C4 Therapeutics Inc ( CCCC ) stock is trading at $8.36, a drop of $1.02, or 11.94%, on low volume.CCCC Stock Price Chart Interactive Chart >. CCCC POWR Grades. CCCC scores best on the Value dimension, with a Value rank ahead of 51.9% of US stocks. CCCC's strongest trending metric is Stability; it's been moving down over the last 178 days. CCCC's current lowest rank is in the Momentum metric (where it is better than 6.79% of US stocks).Aug 22, 2023 · Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for CCCC stock stock is $8.17, which predicts an increase of 151.38%. The lowest target is $3.00 and the highest is $17. On average, analysts rate CCCC stock stock as a hold. Aug 8, 2023 · Net loss per share for the second quarter of 2023 was $0.73 compared to $0.56 for the second quarter of 2022. Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities as of June 30, 2023, were $286.7 million, compared to $337.1 million as of December 31, 2022. The decrease in cash was primarily driven by ... Nov 23, 2022 · -Jupiter Wellness Inc stock is trading at $1.02, a decline of $0.17, or 14.29%, on average volume. Jupiter Wellness Inc. gets a Sentiment Score of Bearish from InvestorsObserver . -C4 Therapeutics Inc ( CCCC ) stock is trading at $8.36, a drop of $1.02, or 11.94%, on low volume. According to . 5 Wall Street analysts that have issued a 1 year CCCC price target, the average CCCC price target is $8.00, with the highest CCCC stock price forecast at $17.00 and the lowest CCCC stock price forecast at $3.00.China Airport Construction Group Corporation entered into an agreement to acquire CCCC Airport Investigation and Design Institute Co., Ltd. from China Harbour Engineering Company Ltd., CCCC-FHDI Engineering Co., Ltd., China Communications Construction Company Limited (SEHK:1800), and China Highway Engineering Consultants Co., Ltd for ... yiou CCCC Stock Price Chart Interactive Chart >. CCCC POWR Grades. CCCC scores best on the Value dimension, with a Value rank ahead of 51.9% of US stocks. CCCC's strongest trending metric is Stability; it's been moving down over the last 178 days. CCCC's current lowest rank is in the Momentum metric (where it is better than 6.79% of US stocks).What this means: InvestorsObserver gives C4 Therapeutics Inc. (CCCC) an overall rank of 45, which is below average. C4 Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 45 means that 55% of stocks appear more favorable to our system. Which C4 Therapeutics insiders have been selling company stock? The following insiders have sold CCCC shares in the last 24 months: Adam Crystal ($681,450.00), Elena Prokupets ($5,927,870.77), Jolie Siegel ($562,500.00), Malcolm Salter ($146,017.00), and Stewart Fisher ($814,680.00).Get the latest C4 Therapeutics Inc (CCCC) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Discover historical prices for CCCC stock on Yahoo Finance. View daily, weekly or monthly format back to when C4 Therapeutics, Inc. stock was issued. Sep 1, 2023 · According to 6 analysts, the average rating for CCCC stock is "Hold." The 12-month stock price forecast is $8.17, which is an increase of 255.22% from the latest price. Discover historical prices for CCCC stock on Yahoo Finance. View daily, weekly or monthly format back to when C4 Therapeutics, Inc. stock was issued.Find the latest Center Coast Brookfield Midstream Foc C (CCCCX) stock quote, history, news and other vital information to help you with your stock trading and investing. lakewood bars Feb 15, 2023 · C4 Therapeutics Inc (CCCC) stock is down -2.56% while the S&P 500 has gained 0.12% as of 2:53 PM on Wednesday, Feb 15. CCCC has fallen -$0.15 from the previous closing price of $5.85 on volume of 186,008 shares. Over the past year the S&P 500 is down -5.92% while CCCC has fallen -74.90%. CCCC lost -$2.19 per share in the over the last 12 months. C4 Therapeutics Inc (CCCC) stock is trading at $3.10 as of 2:06 PM on Monday, Apr 10, a decline of -$0.20, or -6.21% from the previous closing price of $3.30. The stock has traded between $3.07 and $3.51 so far today. Volume today is light. So far 229,641 shares have traded compared to average volume of 616,509 shares.Find the latest CCC Intelligent Solutions Holdings Inc. (CCCS) stock quote, history, news and other vital information to help you with your stock trading and investing.CCCC Stock Overview. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. About the company aya login What is the target price for C4 Therapeutics (CCCC) stock? A. The latest price target for C4 Therapeutics ( NASDAQ: CCCC) was reported by HC Wainwright & Co. on Wednesday, August 9, 2023. The ... the secret life jeffrey dahmer CCCC stock closed at $3.37 and is down -$0.08 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. CCCC has a roughly average overall score of 51 meaning the stock holds a better value than 51% of stocks at its current price.C4 Therapeutics (CCCC) (Delayed Data from NSDQ) $2.30 USD -0.03 (-1.29%) Updated Sep 8, 2023 04:00 PM ET After-Market: $2.30 0.00 (0.00%) 7:58 PM ET Add to portfolio Zacks Rank: 3-Hold 3 Style...Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-2.85 Market Cap $167.74 M Shares Outstanding 49.19 M Public Float 40.07 M Yield CCCC is not currently paying a regular dividend. Latest Dividend...C4 Therapeutics is forecasted to grow earnings and revenue by 11.6% and 72.4% per annum respectively. EPS is expected to grow by 24.8%. Return on equity is forecast to be -90.8% in 3 years.CCCC stock closed at $3.71 and is down -$0.08 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. CCCC has a roughly average overall score of 52 meaning the stock holds a better value than 52% of stocks at its current price.CCCC’s Market Performance. C4 Therapeutics Inc. (CCCC) has experienced a -22.48% fall in stock performance for the past week, with a -32.39% drop in the past month, and a -31.81% drop in the past quarter. The volatility ratio for the week is 7.43%, and the volatility levels for the past 30 days are at 5.05% for CCCC.Aug 4, 2023 · C4 Therapeutics, Inc. (CCCC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. Apr 11, 2022 · After a decline of more than 60% last week, the clinical-stage biotech, C4 Therapeutics (CCCC), continues to trade lower on Monday as the market reacts to the company’s Phase 1/2 data... best eye candy Jul 5, 2023 · That average rating earns the stock an Analyst Ranking of 25, which means it ranks higher than 25 of stocks, based on data compiled by InvestorsObserver. Wall Street analysts are rating CCCC a Buy today. Jul 5, 2023 · WATERTOWN, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science to develop a new generation of small-molecule medicines and transform how disease is treated, Read More. Jul 5, 2023. As of 2023 September 06, Wednesday current price of CCCC stock is 2.670$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception). C4 Therapeutics stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period.May 22, 2023 · Mentioned in this article. CCCC 0.00%. 52. See CCCC Report. InvestorsObserver is giving C4 Therapeutics Inc (CCCC) an Analyst Rating Rank of 24, meaning CCCC is ranked higher by analysts than 24% of stocks. The average price target for CCCC is $21 and analyst’s rate the stock as a Buy. Wall Street analysts are rating CCCC a Buy today. Jul 8, 2023 · The stock is rated as a Hold by 4 analyst(s), 6 recommend it as a Buy and 0 called the CCCC stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 2 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is ... Jan 25, 2023 · C4 Therapeutics Inc (CCCC) stock is trading at $7.59 as of 3:08 PM on Wednesday, Jan 25, a drop of -$0.50, or -6.18% from the previous closing price of $8.09. The stock has traded between $7.14 and $7.88 so far today. Volume today is less active than usual. Sep 13, 2023 · A high-level overview of C4 Therapeutics, Inc. (CCCC) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The stock's open price was 2.955. Stay informed regarding CCCC Stock and understand the value of trading C4 TherapeuticsInc now. Get the latest C4 TherapeuticsInc detailed stock quotes, stock trade data, stock price info, and performance analysis, including CCCC Stock investment advice, charts, stats and more.Find the latest C4 Therapeutics, Inc. (CCCC) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.These Healthcare stocks are trading higher:-Castle Biosciences Inc stock is trading at $20.64, a rise of $7.36, or 54.97%, on high volume.Castle Biosciences Inc gets a Sentiment Score of Very Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $33.63.C4 Therapeutics is forecasted to grow earnings and revenue by 11.6% and 72.4% per annum respectively. EPS is expected to grow by 24.8%. Return on equity is forecast to be -90.8% in 3 years.Jul 5, 2023 · WATERTOWN, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science to develop a new generation of small-molecule medicines and transform how disease is treated, Read More. Jul 5, 2023. The ownership structure of C4 Therapeutics (CCCC) stock is a mix of institutional, retail and individual investors. Approximately 40.73% of the company’s stock is owned by Institutional Investors, 29.79% is owned by Mutual Funds, 0.00% is owned by Insiders and 29.48% is owned by Public Companies and Individual Investors.Complete C4 Therapeutics Inc. stock information by Barron's. View real-time CCCC stock price and news, along with industry-best analysis.That average rating earns the stock an Analyst Ranking of 25, which means it ranks higher than 25 of stocks, based on data compiled by InvestorsObserver. Wall Street analysts are rating CCCC a Buy today. levels of ecological organization Dec 16, 2022 · C4 Therapeutics Inc stock is lower by 10.19% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. C4 Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CCCC! Jezperklauzen/iStock via Getty Images. The shares of C4 Therapeutics ( NASDAQ: CCCC) lost more than half of their value on Friday after the clinical-stage biotech disclosed data from a group of ...Mar 23, 2023 · Insiders who bought US$116k worth of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) stock at an average buy price of US$7.39 over the last year may be disappointed by the recent 13% decrease in the stock ... Jefferies Reaffirms Their Buy Rating on C4 Therapeutics (CCCC) August 11, 2023TipRanks. C4 Therapeutics price target lowered to $17 from $25 at H.C. Wainwright August 9, 2023TipRanks. C4 ... C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL). China Communications Construction Company, Ltd. (CCCC) is a majority state-owned, publicly traded, multinational engineering and construction company primarily engaged in the design, construction and operation of infrastructure assets, including highways, bridges, tunnels, railways (especially high-speed rail), subways, airports, oil platforms, and marine ports.Jul 10, 2023 · CCCC stock closed at $3.37 and is down -$0.08 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. CCCC has a roughly average overall score of 51 meaning the stock holds a better value than 51% of stocks at its current price. The average trading volume of CCCC on July 21, 2023 was 1.26M shares. CCCC) stock’s latest price update. C4 Therapeutics Inc. (NASDAQ: CCCC) has experienced a decline in its stock price by -6.38 compared to its previous closing price of 3.76. However, the company has seen a fall of -3.30% in its stock price over the last five trading days.C4 Therapeutics, Inc. Common Stock (CCCC) Nasdaq Listed 0 No Notifications Add to Watchlist Add to Portfolio Quotes Mar 17, 2023 10:15 am 11:05 am 11:55 am 1:05 pm 2:00 pm 2:50 pm 3:35 pm... Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-2.85 Market Cap $167.74 M Shares Outstanding 49.19 M Public Float 40.07 M Yield CCCC is not currently paying a regular dividend. Latest Dividend...These Healthcare stocks are trading higher:-Castle Biosciences Inc stock is trading at $20.64, a rise of $7.36, or 54.97%, on high volume.Castle Biosciences Inc gets a Sentiment Score of Very Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $33.63.As of February 24, 2023, 4:00 PM CST, C4 Therapeutics Inc’s stock price was $5.33. C4 Therapeutics Inc is down 11.46% from its previous closing price of $6.02. During the last market session, C4 Therapeutics Inc’s stock traded between $5.63 and $6.17. Currently, there are 0.00 million shares of C4 Therapeutics Inc stock available for purchase. jewellery african China Communications Construction Company, Ltd. (CCCC) is a majority state-owned, publicly traded, multinational engineering and construction company primarily engaged in the design, construction and operation of infrastructure assets, including highways, bridges, tunnels, railways (especially high-speed rail), subways, airports, oil platforms, and marine ports. What this means: InvestorsObserver gives C4 Therapeutics Inc. (CCCC) an overall rank of 45, which is below average. C4 Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 45 means that 55% of stocks appear more favorable to our system. nes emulatorThe average trading volume of CCCC on August 31, 2023 was 1.18M shares. CCCC) stock’s latest price update. The stock price of C4 Therapeutics Inc. (NASDAQ: CCCC) has plunged by -4.56 when compared to previous closing price of 3.07, but the company has seen a -11.48% decline in its stock price over the last five trading sessions.C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL).The average trading volume of CCCC on August 31, 2023 was 1.18M shares. CCCC) stock’s latest price update. The stock price of C4 Therapeutics Inc. (NASDAQ: CCCC) has plunged by -4.56 when compared to previous closing price of 3.07, but the company has seen a -11.48% decline in its stock price over the last five trading sessions.According to 6 analysts, the average rating for CCCC stock is "Hold." The 12-month stock price forecast is $8.17, which is an increase of 255.22% from the latest price.C4 Therapeutics stock was originally listed at a price of $25.49 in Oct 2, 2020. If you had invested in C4 Therapeutics stock at $25.49, your return over the last 2 years would have been -90.98%, for an annualized return of -69.96% (not including any dividends or dividend reinvestments).CCCC closed down 0.69 percent on Friday, September 1, 2023, on 17 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.In last trading session, C4 Therapeutics Inc. (NASDAQ:CCCC) saw 0.63 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $4.38 trading at -$0.29 or -6.21% at ring of the bell on the day assigns it a market valuation of $211.25M. That closing the smart cookie CCCC Stock Overview. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. About the companyJefferies Reaffirms Their Buy Rating on C4 Therapeutics (CCCC) August 11, 2023TipRanks. C4 Therapeutics price target lowered to $17 from $25 at H.C. Wainwright August 9, 2023TipRanks. C4 ... The average trading volume of CCCC on July 21, 2023 was 1.26M shares. CCCC) stock’s latest price update. C4 Therapeutics Inc. (NASDAQ: CCCC) has experienced a decline in its stock price by -6.38 compared to its previous closing price of 3.76. However, the company has seen a fall of -3.30% in its stock price over the last five trading days.A score of 58 means the stock is more attractive than 58 percent of stocks. These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score.C4 Therapeutics stock was originally listed at a price of $25.49 in Oct 2, 2020. If you had invested in C4 Therapeutics stock at $25.49, your return over the last 2 years would have been -90.98%, for an annualized return of -69.96% (not including any dividends or dividend reinvestments).In last trading session, C4 Therapeutics Inc. (NASDAQ:CCCC) saw 0.63 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $4.38 trading at -$0.29 or -6.21% at ring of the bell on the day assigns it a market valuation of $211.25M. That closingNov 8, 2022 · See CCCC Report A rating of 70 puts C4 Therapeutics Inc ( CCCC ) near the top of the Healthcare sector according to InvestorsObserver . C4 Therapeutics Inc's score of 70 means that it ranks higher than 70% of stocks in the sector. C4 Therapeutics, Inc. Common Stock (CCCC) Nasdaq Listed 0 No Notifications Add to Watchlist Add to Portfolio Quotes Mar 17, 2023 10:15 am 11:05 am 11:55 am 1:05 pm 2:00 pm 2:50 pm 3:35 pm... mathis brothers okc Find the latest C4 Therapeutics, Inc. (CCCC) stock quote, history, news and other vital information to help you with your stock trading and investing. The market has been down on C4 Therapeutics Inc (CCCC) stock recently. CCCC gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.C4 Therapeutics Inc. Annual balance sheet by MarketWatch. View all CCCC assets, cash, debt, liabilities, shareholder equity and investments.CCCC stock closed at $3.71 and is down -$0.08 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. CCCC has a roughly average overall score of 52 meaning the stock holds a better value than 52% of stocks at its current price.Mar 11, 2023 · In last trading session, C4 Therapeutics Inc. (NASDAQ:CCCC) saw 0.63 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $4.38 trading at -$0.29 or -6.21% at ring of the bell on the day assigns it a market valuation of $211.25M. That closing Browse Getty Images' premium collection of high-quality, authentic Cccc stock photos, royalty-free images, and pictures. Cccc stock photos are available in a variety of sizes and formats to fit your needs.Find the latest C4 Therapeutics, Inc. (CCCC) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. show me my reminders Sep 12, 2023 · What is the target price for C4 Therapeutics (CCCC) stock? A. The latest price target for C4 Therapeutics ( NASDAQ: CCCC) was reported by HC Wainwright & Co. on Wednesday, August 9, 2023. The ... Jan 5, 2023 · C4 Therapeutics, Inc. (CCCC Quick Quote CCCC - Free Report) closed the most recent trading day at $6.51, moving -1.96% from the previous trading session. This change lagged the S&P 500's 1.17% ... C4 Therapeutics, Inc. Common Stock (CCCC) Nasdaq Listed 0 No Notifications Add to Watchlist Add to Portfolio Quotes Mar 17, 2023 10:15 am 11:05 am 11:55 am 1:05 pm 2:00 pm 2:50 pm 3:35 pm... Sep 1, 2023 · According to 6 analysts, the average rating for CCCC stock is "Hold." The 12-month stock price forecast is $8.17, which is an increase of 255.22% from the latest price. What this means: InvestorsObserver gives C4 Therapeutics Inc. (CCCC) an overall rank of 45, which is below average. C4 Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 45 means that 55% of stocks appear more favorable to our system.CCCC stock closed at $3.71 and is down -$0.08 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. CCCC has a roughly average overall score of 52 meaning the stock holds a better value than 52% of stocks at its current price. teleporter CCCC support price is $2.20 and resistance is $2.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CCCC stock will trade within this expected range on the day.C4 Therapeutics Inc (CCCC) stock is trading at $7.59 as of 3:08 PM on Wednesday, Jan 25, a drop of -$0.50, or -6.18% from the previous closing price of $8.09. The stock has traded between $7.14 and $7.88 so far today. Volume today is less active than usual.Nov 8, 2022 · See CCCC Report A rating of 70 puts C4 Therapeutics Inc ( CCCC ) near the top of the Healthcare sector according to InvestorsObserver . C4 Therapeutics Inc's score of 70 means that it ranks higher than 70% of stocks in the sector. Aug 4, 2023 · C4 Therapeutics, Inc. (CCCC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. As of March 1, 2023, C4 Therapeutics Inc’s stock price is $5.05, which is down 4.27% from its previous closing price. At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics ...Sep 13, 2023 · A high-level overview of C4 Therapeutics, Inc. (CCCC) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. C4 Therapeutics stock was originally listed at a price of $25.49 in Oct 2, 2020. If you had invested in C4 Therapeutics stock at $25.49, your return over the last 2 years would have been -90.98%, for an annualized return of -69.96% (not including any dividends or dividend reinvestments).Mar 23, 2023 · Insiders who bought US$116k worth of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) stock at an average buy price of US$7.39 over the last year may be disappointed by the recent 13% decrease in the stock ... joymoviesCCCC Signals & Forecast. There are few to no technical positive signals at the moment. The C4 Therapeutics Inc stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above ...CCCC’s Market Performance. C4 Therapeutics Inc. (CCCC) has experienced a -22.48% fall in stock performance for the past week, with a -32.39% drop in the past month, and a -31.81% drop in the past quarter. The volatility ratio for the week is 7.43%, and the volatility levels for the past 30 days are at 5.05% for CCCC.Jun 2, 2019 · China Airport Construction Group Corporation entered into an agreement to acquire CCCC Airport Investigation and Design Institute Co., Ltd. from China Harbour Engineering Company Ltd., CCCC-FHDI Engineering Co., Ltd., China Communications Construction Company Limited (SEHK:1800), and China Highway Engineering Consultants Co., Ltd for ... Stock Price Forecast. The 12 analysts offering 12-month price forecasts for C4 Therapeutics Inc have a median target of 12.00, with a high estimate of 84.00 and a low estimate of 3.00. The median ...Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Sep 8, 2023 · CCCC Signals & Forecast. There are few to no technical positive signals at the moment. The C4 Therapeutics Inc stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above ... Analysts who follow C4 Therapeutics Inc on average expect it to gain 324.86% over the next twelve months.Those same analysts give the stock an average rating of Buy. That average rating earns CCCC an Analyst Ranking of 33, which means it ranks higher than 33 of stocks, based on data compiled by InvestorsObserChina Airport Construction Group Corporation entered into an agreement to acquire CCCC Airport Investigation and Design Institute Co., Ltd. from China Harbour Engineering Company Ltd., CCCC-FHDI Engineering Co., Ltd., China Communications Construction Company Limited (SEHK:1800), and China Highway Engineering Consultants Co., Ltd for ...Mentioned in this article. CCCC 0.00%. 52. See CCCC Report. InvestorsObserver is giving C4 Therapeutics Inc (CCCC) an Analyst Rating Rank of 24, meaning CCCC is ranked higher by analysts than 24% of stocks. The average price target for CCCC is $21 and analyst’s rate the stock as a Buy. Wall Street analysts are rating CCCC a Buy today. moderated What this means: InvestorsObserver gives C4 Therapeutics Inc. (CCCC) an overall rank of 45, which is below average. C4 Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 45 means that 55% of stocks appear more favorable to our system.CCCC Stock Overview. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. About the company watch the wedding ringerwear weatherbrcc stock}